191 related articles for article (PubMed ID: 32323888)
1. Teriflunomide, a potential novel cause of chronic active colitis.
Kővári B; Zachs J; Murchie B; Lauwers GY
Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
[No Abstract] [Full Text] [Related]
2. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V
Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734
[No Abstract] [Full Text] [Related]
6. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect.
Largeau B; Béra F; Vannier J; Jonville-Béra AP
Fundam Clin Pharmacol; 2021 Oct; 35(5):930-932. PubMed ID: 33458875
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
[TBL] [Abstract][Full Text] [Related]
8. Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?
Pourcher V; Yeung J; Le Pimpec-Barthes F; Maillart E; Gibault L; Boussouar S
Rev Neurol (Paris); 2022 Mar; 178(3):266-267. PubMed ID: 34579947
[No Abstract] [Full Text] [Related]
9. Rebound syndrome in two cases of MS patients after teriflunomide cessation.
Labauge P; Ayrignac X; Prin P; Charif M; Carra-Dalliere C
Acta Neurol Belg; 2022 Oct; 122(5):1381-1384. PubMed ID: 35802339
[No Abstract] [Full Text] [Related]
10. Teriflunomide: Pediatric First Approval.
Paik J
Paediatr Drugs; 2021 Nov; 23(6):609-613. PubMed ID: 34595696
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Vukusic S; Coyle PK; Jurgensen S; Truffinet P; Benamor M; Afsar S; Purvis A; Poole EM; Chambers C
Mult Scler; 2020 Jun; 26(7):829-836. PubMed ID: 30968734
[TBL] [Abstract][Full Text] [Related]
12. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
13. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
14. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
15. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Gerschenfeld G; Servy A; Valeyrie-Allanore L; de Prost N; Cecchini J
Mult Scler; 2015 Oct; 21(11):1476-7. PubMed ID: 26199352
[TBL] [Abstract][Full Text] [Related]
16. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
[No Abstract] [Full Text] [Related]
18. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Camara-Lemarroy CR; Castilló J; Sastre-Garriga J; Tintore M; Montalban X
Mult Scler; 2018 Sep; 24(10):1383-1385. PubMed ID: 29473796
[TBL] [Abstract][Full Text] [Related]
19. Palmar pustular psoriasis associated with teriflunomide treatment.
Negrotto L; Correale J
Mult Scler Relat Disord; 2019 Jan; 27():400-402. PubMed ID: 30513502
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory colitis associated with Teriflunomide.
Esfahani NZ; von Geldern G; Romba MC; Parikh DA; Wundes A
Mult Scler Relat Disord; 2020 Nov; 46():102480. PubMed ID: 32942118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
